Literature DB >> 25549724

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.

Murali Janakiram1, Jordan M Chinai2, Susan Fineberg3, Andras Fiser4, Cristina Montagna5, Ramadevi Medavarapu3, Ekaterina Castano6, Hyungjun Jeon2, Kim C Ohaegbulam2, Ruihua Zhao2, Aimin Zhao7, Steven C Almo8, Joseph A Sparano9, Xingxing Zang10.   

Abstract

PURPOSE: HHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 family member that regulates human T-cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2 protein expression in normal human tissues and cancers, as well as its prognostic significance, to explore mechanisms regulating HHLA2 expression, and to identify candidate HHLA2 receptors. EXPERIMENTAL
DESIGN: An immunohistochemistry protocol and a flow cytometry assay with newly generated monoclonal antibodies were developed to examine HHLA2 protein. HHLA2 gene copy-number variation was analyzed from cancer genomic data. The combination of bioinformatics analysis and immunologic approaches was established to explore HHLA2 receptors.
RESULTS: HHLA2 protein was detected in trophoblastic cells of the placenta and the epithelium of gut, kidney, gallbladder, and breast, but not in most other organs. In contrast, HHLA2 protein was widely expressed in human cancers from the breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, and esophagus. In a cohort of 50 patients with stage I-III triple-negative breast cancer, 56% of patients had aberrant expression of HHLA2 on their tumors, and high HHLA2 expression was significantly associated with regional lymph node metastasis and stage. The Cancer Genome Atlas revealed that HHLA2 copy-number gains were present in 29% of basal breast cancers, providing a potential mechanism for increased HHLA2 protein expression in breast cancer. Finally, Transmembrane and Immunoglobulin Domain Containing 2 (TMIGD2) was identified as one of the receptors for HHLA2.
CONCLUSIONS: Wide expression of HHLA2 in human malignancies, together with its association with poor prognostic factors and its T-cell coinhibitory capability, suggests that the HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25549724      PMCID: PMC4433806          DOI: 10.1158/1078-0432.CCR-14-1495

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  B7x: a widely expressed B7 family member that inhibits T cell activation.

Authors:  Xingxing Zang; P'ng Loke; Jayon Kim; Kenneth Murphy; Rebecca Waitz; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

Review 2.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

Review 3.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Functional classification of immune regulatory proteins.

Authors:  Rotem Rubinstein; Udupi A Ramagopal; Stanley G Nathenson; Steven C Almo; Andras Fiser
Journal:  Structure       Date:  2013-04-11       Impact factor: 5.006

8.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

Review 9.  Yin-Yang of costimulation: crucial controls of immune tolerance and function.

Authors:  Roza I Nurieva; Xikui Liu; Chen Dong
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Functional clustering of immunoglobulin superfamily proteins with protein-protein interaction information calibrated hidden Markov model sequence profiles.

Authors:  Eng-Hui Yap; Tyler Rosche; Steve Almo; Andras Fiser
Journal:  J Mol Biol       Date:  2013-11-16       Impact factor: 5.469

View more
  69 in total

1.  HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.

Authors:  Li Wei; Liang Tang; Haiyan Chang; Song Huo; Yan Li
Journal:  Hum Cell       Date:  2019-09-24       Impact factor: 4.174

2.  CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.

Authors:  Yu Tian; Yi Sun; Fan Gao; Michelle R Koenig; Alexander Sunderland; Yuki Fujiwara; Robert J Torphy; Lieping Chen; Barish H Edil; Richard D Schulick; Yuwen Zhu
Journal:  Oncoimmunology       Date:  2018-11-05       Impact factor: 8.110

3.  Phenotype and tissue distribution of CD28H+ immune cell subsets.

Authors:  Joel Crespo; Linda Vatan; Tomasz Maj; Rebecca Liu; Ilona Kryczek; Weiping Zou
Journal:  Oncoimmunology       Date:  2017-08-16       Impact factor: 8.110

4.  HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.

Authors:  Han Yan; Wanglong Qiu; Anne K Koehne de Gonzalez; Ji-Shu Wei; Min Tu; Chun-Hua Xi; Ye-Ran Yang; Yun-Peng Peng; Wei-Yann Tsai; Helen E Remotti; Yi Miao; Gloria H Su
Journal:  Cancer Lett       Date:  2018-11-14       Impact factor: 8.679

Review 5.  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Authors:  Alexander Sankin; Deepa Narasimhulu; Peter John; Benjamin Gartrell; Mark Schoenberg; Xingxing Zang
Journal:  Urol Oncol       Date:  2017-05-08       Impact factor: 3.498

Review 6.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

8.  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Authors:  Haiying Cheng; Alain Borczuk; Murali Janakiram; Xiaoxin Ren; Juan Lin; Amer Assal; Balazs Halmos; Roman Perez-Soler; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2018-01-26       Impact factor: 12.531

Review 9.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 10.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.